Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the northeastern German society of gynecological oncology

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 317-322

  Oskay Ozcelik G ^a   Chekerov, R ^a   Sommer, H ^b   Keil, E ^c   Einenkel, J ^d   Pfisterer, J ^e   Lorenz Schluter C ^a   Lichtenegger, W ^a   Camara, O ^f   Sehouli, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HELIOS Hospital Berlin   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Carboplatin; Clinical trials, phase II; Ovarian cancer; Paclitaxel; Sequential first line chemotherapy

Indexed keywords

CARBOPLATIN; ERYTHROPOIETIN; HEMOGLOBIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYSTERECTOMY; INTESTINE RESECTION; LOW DRUG DOSE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MUCINOUS CARCINOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75949115909     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.031     Document Type: Article

References (31)

1. du Bois A., Quinn M., Thigpen T., et al., Gynecologic Cancer Intergroup, AGO-OVAR, ANZGOG, EORTC, GEICO, GINECO, GOG, JGOG, MRC/NCRI, NCIC-CTG, NCI-US, NSGO, RTOG, SGCTG, IGCS, Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16 (2005) 8-12
2. Lichtenegger W., Sehouli J., Buchmann E., et al. Operative results after primary and secondary debulking-operations in advanced ovarian cancer. J. Obstet. Gyn. Res. 24 (1998) 447-451
3. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 77 (1989) 1561-1565
4. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2 (1996) 1843-1849
5. Liebmann J.E., Cook J.A., Lipschultz C., et al. Cytotoxic studies of paclitaxel (taxol) in human tumour cell lines. Br. J. Cancer 68 (1993) 1104-1109
6. Lopes N.M., Adams E.G., Pitts T.W., et al. Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32 (1993) 235-242
7. Sehouli J., Stengel D., Elling D., et al. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol. Oncol. 85 (2002) 321-326
8. Safra T., Bernstein Molho R., Grisaru D., et al. A phase-II study evaluatin safety and efficacy with weekly paclitaxel and carboplatin as a primary treatment for patients with advanced epithelial ovarian cancer (EOC). J. Clin. Oncol. 24 (2006) 5077 abstract
9. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7 (1989) 1748-1756
10. Jelliffe R.W. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79 (1973) 604-605
11. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30.html.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000) 205-216
13. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 (1996) 1545-1551
14. Pfisterer J., Weber B., Reuss A., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl. Cancer Inst. 98 (2006) 1024-1026
15. Bookman M.A., Brady M.F., McGuire W.P., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 (2009) 1419-1425
16. Marth C., Windbichler G.H., Hausmaninger H., et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gyn. Cancer 16 (2006) 1522-1528
17. Berek J.S. Interferon plus chemotherapy for primary treatment of ovarian cancer, commentary. Lancet 356 (2000) 6-7
18. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 103 (2006) 783-792
19. Sehouli J., Stengel D., Mustea A., et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother. Pharmacol. 61 (2008) 243-250
20. Katsumata N., Watanabe T., Mukai H., et al. A phase II trial of weekly paclitaxel/carboplatin as salvage chemotherapy in patients with relapsed ovarian cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 19 (2001) 865
21. Kumagai M., Fujii T., Komatsu M., Kusuda T., et al. Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration. Gan To Kagaku Ryoho 31 (2004) 555-559
22. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol. 101 (2006) 436-440
23. Fotopoulou C., du Bois A., Alexandros N., et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J. Clin. Oncol. 26 (2008) 2683-2689
24. Douglas Rizzo J., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J. Clin. Oncol. 26 (2007) 1174-1192
25. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 18 (2003) 1255-1260
26. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23 (2005) 5960-5972
27. Smith Jr. R.E., Aapro M.S., Ludwig H., et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26 (2008) 1040-1050
28. FDA information for healthcare professionals: erythropoiesis stimulating agents (ESA). Review date: September 2008.
29. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin vs paclitaxel vs cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynaecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 106-115
30. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
31. Isonishi S., Yasuda M., Takahashi F., et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology [abstract]. J. Clin. Oncol. 26 (2008) 5506